Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Risk stratification of patients diagnosed with gastrointestinal stromal tumor.
